Brokerages Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $12.50

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $12.50.

ALXO has been the subject of several recent research reports. UBS Group lowered their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Monday, August 12th. Lifesci Capital lowered ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th.

ALX Oncology Stock Up 2.0 %

Shares of ALX Oncology stock opened at $1.52 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.39 and a current ratio of 4.39. ALX Oncology has a 52-week low of $1.34 and a 52-week high of $17.83. The stock has a market capitalization of $80.06 million, a price-to-earnings ratio of -0.42 and a beta of 1.03. The company’s 50 day moving average price is $1.83 and its 200-day moving average price is $6.35.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.01. Equities research analysts forecast that ALX Oncology will post -3.04 EPS for the current year.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently made changes to their positions in ALXO. CANADA LIFE ASSURANCE Co purchased a new position in shares of ALX Oncology during the 1st quarter valued at about $27,000. EntryPoint Capital LLC purchased a new position in ALX Oncology in the 1st quarter worth approximately $32,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after purchasing an additional 5,200 shares in the last quarter. Rhumbline Advisers lifted its holdings in ALX Oncology by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after purchasing an additional 5,360 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in ALX Oncology by 50.7% in the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares in the last quarter. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.